Eris Lifesciences Limited announced the execution of a Corporate Guarantee amounting to INR 75 Crores. This guarantee supports a Term Loan sanctioned by HDFC Bank to its Wholly Owned Subsidiary, Eris Bionxt Private Limited (EBPL). The loan proceeds are designated for repaying EBPL’s existing loan liabilities. The company confirmed that promoters hold no interest in this specific transaction, which was executed on March 27, 2026.
Disclosure of Corporate Guarantee Execution
Eris Lifesciences Limited formally disclosed the execution of a Corporate Guarantee, a regulatory filing made on 27 March 2026. This action was taken in compliance with disclosure requirements concerning material events and transactions.
Key Transaction Details
The core of the disclosure revolves around the guarantee provided to secure financing for a subsidiary:
- Beneficiary Party: HDFC Bank, which sanctioned a Term Loan.
- Guaranteed Entity: Eris Bionxt Private Limited (“EBPL”), which is a Wholly Owned Subsidiary of Eris Lifesciences.
- Guarantee Amount: The total guarantee amount sanctioned is INR 75,00,00,000/- (Indian Rupees Seventy Five Crores).
- Purpose of Loan: The Term Loan availed by EBPL will be used specifically for the repayment of its existing loan liabilities.
- Date of Guarantee Deed: The Deed of Guarantee was entered into on March 27, 2026.
Relationship and Interest Disclosure
The announcement explicitly detailed the relationship between the listed entity and the guaranteed party:
EBPL is confirmed as a Wholly Owned Subsidiary of the Company, and its financials are fully consolidated with the parent company’s results. Importantly, the disclosure confirms that the Promoter/promoter group/group companies have no interest in this specific transaction. The terms of the guarantee are managed such that the transaction is conducted on an “arms-length” basis.
Financial Impact on Listed Entity
Regarding the financial standing, the issued corporate guarantee will be reflected as a contingent liability in the standalone financial statements of Eris Lifesciences Limited, although EBPL’s operations and liabilities are already integrated into the consolidated figures.
Source: BSE
